Eque-cel cell therapy for relapsed/refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new cell therapy called Eque-cel, which is designed to target and kill cancer cells in people with multiple myeloma that has returned or is hard to treat after at least three prior therapies. The treatment uses your own immune cells that are modified to fight the myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have multiple myeloma that came back (relapsed) or does not respond to treatment (refractory), after at least three prior treatments including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
- Your disease has measurable markers in your blood or urine (certain levels of M-protein or free light chains).
- Your heart, liver, kidneys, and blood counts are working well enough (based on blood tests and heart scan).
- You have not had prior treatment with a BCMA-targeted therapy or a stem cell transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a new treatment called equecabtagene autoleucel for people whose multiple myeloma has come back or stopped responding to other treatments. It aims to see how well this therapy works in real-world medical settings.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.